Nora K Horick

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4481206/publications.pdf

Version: 2024-02-01

103 papers

3,645 citations

304743 22 h-index 57 g-index

103 all docs

103
docs citations

103 times ranked 7611 citing authors

#	Article	IF	CITATIONS
1	Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. New England Journal of Medicine, 2020, 383, 2333-2344.	27.0	1,102
2	Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19. JAMA - Journal of the American Medical Association, 2021, 326, 499.	7.4	498
3	Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment. JAMA Oncology, 2015, 1, 943.	7.1	294
4	The Impact of Radiation Therapy on the Risk of Lymphedema After Treatment for Breast Cancer: A Prospective Cohort Study. International Journal of Radiation Oncology Biology Physics, 2014, 88, 565-571.	0.8	203
5	Impact of Ipsilateral Blood Draws, Injections, Blood Pressure Measurements, and Air Travel on the Risk of Lymphedema for Patients Treated for Breast Cancer. Journal of Clinical Oncology, 2016, 34, 691-698.	1.6	136
6	Clinicopathologic Features of Non–Small-Cell Lung Cancer Harboring an <i>NTRK</i> Gene Fusion. JCO Precision Oncology, 2018, 2018, 1-12.	3.0	112
7	Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk – Combined Results from Two Screening Trials. Clinical Cancer Research, 2017, 23, 3628-3637.	7.0	99
8	Safety of Combined PD-1 Pathway Inhibition and Intracranial Radiation Therapy in Non–Small Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 550-558.	1.1	95
9	Effectiveness of Integrated Palliative and Oncology Care for Patients With Acute Myeloid Leukemia. JAMA Oncology, 2021, 7, 238.	7.1	90
10	Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers. Clinical Cancer Research, 2020, 26, 1877-1885.	7. O	67
11	Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial. Blood, 2022, 139, 2306-2315.	1.4	62
12	Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dose-painted IMRT per RTOG 0529. Advances in Radiation Oncology, 2017, 2, 110-117.	1,2	45
13	Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy. Leukemia, 2019, 33, 2393-2402.	7.2	44
14	Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)., 2022, 10, e003847.		44
15	The Impact of Chest Wall Boost on Reconstruction Complications and Local Control in Patients Treated for Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 105, 155-164.	0.8	35
16	Radiation Therapy Risk Factors for Development of Lymphedema in Patients Treated With Regional Lymph Node Irradiation for Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 91, 760-764.	0.8	34
17	Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor–Positive Breast Cancer. Cancer Discovery, 2018, 8, 336-353.	9.4	32
18	Multimodal psychosocial intervention for family caregivers of patients undergoing hematopoietic stem cell transplantation: A randomized clinical trial. Cancer, 2020, 126, 1758-1765.	4.1	32

#	Article	IF	CITATIONS
19	Diagnostic Accuracy of Endobronchial Optical Coherence Tomography for the Microscopic Diagnosis of Usual Interstitial Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 1164-1179.	5. 6	32
20	Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy. Breast Cancer Research, 2015, 17, 56.	5.0	30
21	Hypofractionated Radiation Therapy for Unresectable/Locally Recurrent Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2020, 27, 1122-1129.	1.5	29
22	Adherence to Recommended Risk Management among Unaffected Women with a <i>BRCA</i> Mutation. Journal of Genetic Counseling, 2017, 26, 79-92.	1.6	28
23	Proton Radiation Therapy for Pediatric Craniopharyngioma. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1480-1487.	0.8	27
24	Knowledge and Uptake of Genetic Counseling and Colonoscopic Screening Among Individuals at Increased Risk for Lynch Syndrome and their Endoscopists from the Family Health Promotion Project. American Journal of Gastroenterology, 2016, 111, 285-293.	0.4	24
25	Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes. Annals of Surgical Oncology, 2020, 27, 1400-1406.	1.5	22
26	Factors Associated With Fear of Lymphedema After Treatment for Breast Cancer. Oncology Nursing Forum, 2014, 41, 473-483.	1.2	20
27	Sexual Function, Quality of Life, and Mood After Radiation Therapy in Patients with Anal Cancer. Journal of Gastrointestinal Cancer, 2020, 51, 204-210.	1.3	20
28	The Patient's Voice: Adherence, Symptoms, and Distress Related to Adjuvant Endocrine Therapy After Breast Cancer. International Journal of Behavioral Medicine, 2020, 27, 687-697.	1.7	19
29	Effects of a perioperative geriatric intervention for older adults with Cancer: A randomized clinical trial. Journal of Geriatric Oncology, 2022, 13, 410-415.	1.0	19
30	Practice, Preferences, and Practical Tips From Primary Care Physicians to Improve the Care of Cancer Survivors. Journal of Oncology Practice, 2019, 15, e600-e606.	2.5	18
31	High IDO1 Expression Is Associated with Poor Outcome in Patients with Anal Cancer Treated with Definitive Chemoradiotherapy. Oncologist, 2019, 24, e275-e283.	3.7	18
32	Physical and psychological health in rare cancer survivors. Journal of Cancer Survivorship, 2017, 11, 158-165.	2.9	16
33	Perceptions of prognosis and goal of treatment in patients with malignant gliomas and their caregivers. Neuro-Oncology Practice, 2020, 7, 490-497.	1.6	16
34	FOLFOX plus zivâ€aflibercept or placebo in firstâ€line metastatic esophagogastric adenocarcinoma: A doubleâ€blind, randomized, multicenter phase 2 trial. Cancer, 2019, 125, 2213-2221.	4.1	14
35	Moving forward on all fronts: impact, patterns, and barriers to exercise in cancer survivors and patients living with advanced disease. Supportive Care in Cancer, 2020, 28, 4979-4988.	2.2	14
36	Posttraumatic stress disorder symptoms in patients with acute myeloid leukemia. Cancer, 2021, 127, 2500-2506.	4.1	14

#	Article	IF	Citations
37	Integrating Symptoms Into the Diagnostic Criteria for Breast Cancer–Related Lymphedema: Applying Results From a Prospective Surveillance Program. Physical Therapy, 2020, 100, 2186-2197.	2.4	13
38	The Impact of an Introductory Radiation Oncology Curriculum (IROC) for Radiation Oncology Trainees Across the United States and Canada. International Journal of Radiation Oncology Biology Physics, 2020, 107, 408-416.	0.8	13
39	Effect of a Symptom Monitoring Intervention for Patients Hospitalized With Advanced Cancer. JAMA Oncology, 2022, 8, 571.	7.1	13
40	Clinical Grade "SNaPshot―Genetic Mutation Profiling in Multiple Myeloma. EBioMedicine, 2015, 2, 71-73.	6.1	12
41	Interleukin-6 inhibitors reduce mortality in coronavirus disease-2019: An individual patient data meta-analysis from randomized controlled trials. European Journal of Internal Medicine, 2022, 101, 41-48.	2.2	12
42	Physical symptoms in long-term survivors of rare cancer. Journal of Cancer Survivorship, 2018, 12, 835-842.	2.9	11
43	Chemoradiationâ€Related Lymphopenia and Its Association with Survival in Patients with Squamous Cell Carcinoma of the Anal Canal. Oncologist, 2020, 25, 1015-1022.	3.7	11
44	Screening Tool Identifies Older Adults With Cancer at Risk for Poor Outcomes. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 305-313.	4.9	10
45	Muscle Loss Is Associated with Overall Survival in Patients with Metastatic Colorectal Cancer Independent of Tumor Mutational Status and Weight Loss. Oncologist, 2021, 26, e963-e970.	3.7	9
46	Multisite randomized trial of integrated palliative and oncology care for patients with acute myeloid leukemia (AML) Journal of Clinical Oncology, 2020, 38, 12000-12000.	1.6	9
47	Prognostic significance of indeterminate lung nodules in renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 355-361.	1.6	7
48	Impact of the elimination of cost sharing for mammographic breast cancer screening among rural US women: A natural experiment. Cancer, 2017, 123, 2506-2515.	4.1	7
49	Patient Preferences for Use of Archived Biospecimens from Oncology Trials When Adequacy of Informed Consent Is Unclear. Oncologist, 2020, 25, 78-86.	3.7	7
50	Associations of baseline patientâ€reported outcomes with treatment outcomes in advanced gastrointestinal cancer. Cancer, 2021, 127, 619-627.	4.1	7
51	Management and outcomes of men diagnosed with primary breast cancer. Breast Cancer Research and Treatment, 2021, 188, 561-569.	2.5	7
52	Randomized trial of a hospice video educational tool for patients with advanced cancer and their caregivers. Cancer, 2020, 126, 3569-3578.	4.1	6
53	Fractionated Proton Radiation Therapy and Hearing Preservation for Vestibular Schwannoma: Preliminary Analysis of a Prospective Phase 2 Clinical Trial. Neurosurgery, 2022, 90, 506-514.	1.1	6
54	Are rare cancer survivors at elevated risk of subsequent new cancers?. BMC Cancer, 2019, 19, 166.	2.6	5

#	Article	IF	CITATIONS
55	Palliative care for patients undergoing stem cell transplant: intervention components and supportive care measures. Bone Marrow Transplantation, 2021, 56, 1971-1977.	2.4	5
56	Clinical Outcomes, Treatment Toxicity, and Health Care Utilization in Older Adults with Aggressive <scp>Non-Hodgkin</scp> Lymphoma. Oncologist, 2021, 26, 965-973.	3.7	5
57	Clinical and molecular features of patients with cholangiocarcinoma harboring FGFR genetic alterations Journal of Clinical Oncology, 2019, 37, 4084-4084.	1.6	5
58	Do you mind if I record?: Perceptions and practice regarding patient requests to record clinic visits in oncology. Cancer, 2022, 128, 275-283.	4.1	5
59	FIT: Functional and imaging testing for patients with metastatic cancer Journal of Clinical Oncology, 2018, 36, 208-208.	1.6	5
60	Phase 1 Study of CD37-Directed CAR T Cells in Patients with Relapsed or Refractory CD37+ Hematologic Malignancies. Blood, 2021, 138, 653-653.	1.4	5
61	Pilot study to assess prolonged overnight fasting in breast cancer survivors (longfast). Breast Cancer Research and Treatment, 2022, , .	2.5	5
62	Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy. European Journal of Cancer, 2016, 56, 85-92.	2.8	4
63	Patterns of Failure and the Need for Biliary Intervention in Resected Biliary Tract Cancers After Chemoradiation. Annals of Surgical Oncology, 2020, 27, 5161-5172.	1.5	4
64	Neoadjuvant versus Postoperative Chemoradiotherapy is Associated with Improved Survival for Patients with Resectable Gastric and Gastroesophageal Cancer. Annals of Surgical Oncology, 2022, 29, 242-252.	1.5	4
65	Phase II trial of a PARP inhibitor in somatic BRCA mutant metastatic breast cancer Journal of Clinical Oncology, 2020, 38, TPS1113-TPS1113.	1.6	3
66	Hybrid laryngotracheal reconstruction vs single and double stage: Indications and outcomes. International Journal of Pediatric Otorhinolaryngology, 2021, 151, 110948.	1.0	3
67	Factors associated with psychological distress in caregivers of patients with malignant gliomas. Supportive Care in Cancer, 2022, 30, 5811-5820.	2.2	3
68	Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinumâ€sensitive ovarian, fallopian tube, or primary peritoneal cancer. Cancer, 2016, 122, 3297-3306.	4.1	2
69	Phase II multicenter study of talazoparib for somatic <i>BRCA1/2</i> mutant metastatic breast cancer Journal of Clinical Oncology, 2021, 39, TPS1110-TPS1110.	1.6	2
70	Early Mortality in Newly Diagnosed Multiple Myeloma in the Context of Novel Drugs. Blood, 2015, 126, 3315-3315.	1.4	2
71	CACHEXIO: Evaluation of body composition changes and immunotherapy in patients with metastatic cancer Journal of Clinical Oncology, 2018, 36, 209-209.	1.6	2
72	Aggressiveness of care and overall survival in young metastatic colorectal cancer patients Journal of Clinical Oncology, 2019, 37, 3563-3563.	1.6	2

#	Article	IF	CITATIONS
73	Reply to: Endobronchial Optical Coherence Tomography: Shining New Light on Diagnosing UIP?. American Journal of Respiratory and Critical Care Medicine, 2022, , .	5.6	2
74	A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma Journal of Clinical Oncology, 2022, 40, 8012-8012.	1.6	2
75	Discrepancy in risk assessment of hormone receptor positive early-stage breast cancer patients using breast cancer index and recurrence score. Breast Cancer Research and Treatment, 2019, 173, 375-383.	2.5	1
76	Feasibility of integrating the Outcomes4Me smartphone navigation application into the care of breast cancer patients (FIONA) Journal of Clinical Oncology, 2021, 39, 1570-1570.	1.6	1
77	Clinical and mutational profile of ARID1A-mutated gastrointestinal cancers: Duration of response to platinum-based chemotherapy Journal of Clinical Oncology, 2021, 39, e15611-e15611.	1.6	1
78	Multicenter phase II trial of pembrolizumab (pembro) in previously-treated metastatic esophageal cancer Journal of Clinical Oncology, 2018, 36, e16072-e16072.	1.6	1
79	Post-Traumatic Stress Disorder (PTSD) Symptoms in Patients with Acute Myeloid Leukemia (AML). Blood, 2020, 136, 44-45.	1.4	1
80	Associations of sarcopenia with hematologic toxicity, treatment intensity, and healthcare utilization in patients with metastatic colorectal cancer Journal of Clinical Oncology, 2022, 40, 84-84.	1.6	1
81	QOLP-17. FACTORS ASSOCIATED WITH PSYCHOLOGICAL DISTRESS IN CAREGIVERS OF PATIENTS WITH MALIGNANT GLIOMAS. Neuro-Oncology, 2019, 21, vi201-vi201.	1.2	0
82	Abstract OT-30-02: Phase II study of talazoparib, a PARP inhibitor, in somaticBRCA1/2mutant metastatic breast cancer., 2021,,.		0
83	Survival outcomes, treatment toxicity, and healthcare utilization in older adults with aggressive non-Hodgkin lymphoma (NHL) Journal of Clinical Oncology, 2021, 39, 7557-7557.	1.6	0
84	Changes in patient-reported outcomes (PROs) and tumor markers (TMs) to predict treatment response and survival outcomes in patients with metastatic gastrointestinal (GI) cancer Journal of Clinical Oncology, 2021, 39, 6560-6560.	1.6	0
85	ASO Visual Abstract:ÂNeoadjuvant versusÂPostoperative Chemoradiotherapy Is Associated with Improved Survival in Patients with Resectable Gastric and Gastroesophageal Cancer. Annals of Surgical Oncology, 2021, 28, 690-691.	1.5	0
86	Changes in patient-reported outcomes (PROs) and tumor markers (TMs) to predict treatment response and survival in patients with metastatic gastrointestinal (GI) cancer Journal of Clinical Oncology, 2021, 39, 154-154.	1.6	0
87	Prognostic significance of indeterminate lung nodules in renal cell carcinoma Journal of Clinical Oncology, 2013, 31, 377-377.	1.6	0
88	Late effects in rare cancer registrants Journal of Clinical Oncology, 2014, 32, e20577-e20577.	1.6	0
89	Clinical grade "SNaPshot" genetic mutation profiling in multiple myeloma Journal of Clinical Oncology, 2014, 32, e19571-e19571.	1.6	0
90	Patient-reported priorities for survivorship care and experience discussing available services Journal of Clinical Oncology, 2017, 35, 200-200.	1.6	0

#	Article	IF	CITATIONS
91	The individualized Goals of Care Discussion Guide: A simple tool to empower patients with metastatic breast cancer Journal of Clinical Oncology, 2019, 37, 11622-11622.	1.6	O
92	The role of circulating tumor DNA (ctDNA), tumor markers (TMs), and patient-reported outcomes (PROs) in predicting treatment response in patients with metastatic gastrointestinal (GI) cancer Journal of Clinical Oncology, 2020, 38, 833-833.	1.6	0
93	Chemoradiation-related lymphopenia and its association with survival in patients with anal cancer Journal of Clinical Oncology, 2020, 38, 3-3.	1.6	0
94	Medical oncologists' perceptions of clinical trials for underrepresented populations Journal of Clinical Oncology, 2020, 38, e19062-e19062.	1.6	0
95	Relationships among skeletal muscle, symptom burden, health care use, and survival in hospitalized patients with advanced cancer Journal of Clinical Oncology, 2020, 38, 7006-7006.	1.6	0
96	Randomized trial of a symptom monitoring intervention for hospitalized patients with advanced cancer (NCT03396510) Journal of Clinical Oncology, 2020, 38, 12014-12014.	1.6	0
97	Comparison of the clinical features, treatment patterns, and tumor mutations of patients with intrahepatic (ICC) and extrahepatic (ECC) cholangiocarcinoma Journal of Clinical Oncology, 2020, 38, 580-580.	1.6	0
98	Oncologist experiences regarding patient-recorded clinical encounters: Implications for the patient-doctor relationship Journal of Clinical Oncology, 2020, 38, 290-290.	1.6	0
99	Use of patient-reported outcomes (PROs) to predict treatment outcomes in patients with advanced cancer Journal of Clinical Oncology, 2020, 38, 186-186.	1.6	0
100	Abstract OT2-24-03: Phase II study of a PARP inhibitor in metastatic breast cancer with somatic <i>BRCA1/2</i> mutations identified by cell-free DNA: Genotyping based clinical trial. Cancer Research, 2022, 82, OT2-24-03-OT2-24-03.	0.9	0
101	Abstract P4-12-08: Accuracy of Patient Self-Reported Breast Cancer Disease Characteristics Compared to the Medical Record in a Trial of the Outcomes4MeDigital Health App. Cancer Research, 2022, 82, P4-12-08-P4-12-08.	0.9	0
102	Abstract PD5-11: Pilot study to assess prolonged nightly fasting in breast cancer survivors (LONGFAST). Cancer Research, 2022, 82, PD5-11-PD5-11.	0.9	0
103	Changes in Functional Assessment of Cancer Therapy: General (FACT-G) to predict treatment response and survival outcomes in patients with metastatic gastrointestinal (GI) cancer Journal of Clinical Oncology, 2022, 40, 6570-6570.	1.6	0